BriaCell Therapeutics Warrant
BCTXL
10 hedge funds and large institutions have $2.53M invested in BriaCell Therapeutics Warrant in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 5 closing their positions.
22.13% less ownership
Funds ownership: 127.95% → 105.82% (-22%)
32% less capital invested
Capital invested by funds: $3.7M → $2.53M (-$1.17M)
33% less funds holding
Funds holding: 15 → 10 (-5)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$41.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$176K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$141K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$125K |
| 4 |
HCM
Heights Capital Management
San Francisco,
California
|
-$105K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$83.8K |
BCTXL Hedge Fund Activity: Q2 2026 in Review
10 of the 8,329 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics Warrant (BCTXL) for Q2 2026, worth a combined $2.53M — down 32% from $3.7M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BCTXL and 0 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 1 added.
The largest buyer was Warberg Asset Management, adding an estimated $41.2K. The largest seller was Sabby Management, cutting an estimated $176K.
- 10 institutional investors held BriaCell Therapeutics Warrant (BCTXL) as of Q2 2026, down from 15 in Q1 2026.
- Funds reported $2.53M of BriaCell Therapeutics Warrant stock for Q2 2026, down 32% quarter-over-quarter.
- 0 funds opened new BriaCell Therapeutics Warrant positions in Q2 2026 and 5 closed out, a net change of -5 holders.
- The largest BriaCell Therapeutics Warrant buyer in Q2 2026 was Warberg Asset Management, an estimated $41.2K added.
- The largest BriaCell Therapeutics Warrant seller in Q2 2026 was Sabby Management, an estimated $176K sold.
Based on aggregated 13F filings for Q2 2026.